EUA
cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test
FDA Emergency Use Authorization · Roche Molecular Systems, Inc. · Aug 9, 2024
Key facts
| Product | cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test |
|---|---|
| Company | Roche Molecular Systems, Inc. |
| Product type | RT-PCR, Multiple Targets, Multi-analyte |
| Date | Aug 9, 2024 |
| FDA page | fda.gov |
At a glance
- 1–9 Authorization documents
- 1–9 EUAs for this company
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Emergency Use Authorizations
Emergency Use Authorizations allow the FDA to permit unapproved medical products, or unapproved uses of approved products, during a declared public health emergency.
Source: U.S. Food and Drug Administration (FDA), Emergency Use Authorizations · Source date: